Gyre Therapeutics, based in San Diego, CA, is a biopharmaceutical company with a primary focus on developing and bringing to market Hydronidone (F351) for treating Metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Formerly known as Nonalcoholic Steatohepatitis (NASH), MASH fibrosis is the target condition for Hydronidone, currently under evaluation for the treatment of liver fibrosis in various...
Gyre Therapeutics, based in San Diego, CA, is a biopharmaceutical company with a primary focus on developing and bringing to market Hydronidone (F351) for treating Metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Formerly known as Nonalcoholic Steatohepatitis (NASH), MASH fibrosis is the target condition for Hydronidone, currently under evaluation for the treatment of liver fibrosis in various chronic liver diseases in the United States. The drug is being assessed under an active Investigational New Drug (IND) application.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.